Regencell Bioscience Net Worth
Regencell Bioscience Net Worth Breakdown | RGC |
Regencell Bioscience Net Worth Analysis
Regencell Bioscience's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Regencell Bioscience's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Regencell Bioscience's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Regencell Bioscience's net worth analysis. One common approach is to calculate Regencell Bioscience's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Regencell Bioscience's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Regencell Bioscience's net worth. This approach calculates the present value of Regencell Bioscience's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Regencell Bioscience's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Regencell Bioscience's net worth. This involves comparing Regencell Bioscience's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Regencell Bioscience's net worth relative to its peers.
To determine if Regencell Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Regencell Bioscience's net worth research are outlined below:
Regencell Bioscience is way too risky over 90 days horizon | |
Regencell Bioscience appears to be risky and price may revert if volatility continues | |
Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0. | |
Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
Roughly 94.0% of the company outstanding shares are owned by corporate insiders |
Regencell Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Regencell Bioscience Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regencell Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of January 2024 Upcoming Quarterly Report | View | |
30th of September 2023 Next Fiscal Quarter End | View |
Follow Regencell Bioscience's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 533.53 M.Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regencell Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yemenidjian Alex over two weeks ago Acquisition by Yemenidjian Alex of 4977 shares of Regencell Bioscience at 22.1 subject to Rule 16b-3 | ||
Ownby David over two months ago Acquisition by Ownby David of 19416 shares of Regencell Bioscience subject to Rule 16b-3 | ||
Bell Thomas D Jr over three months ago Acquisition by Bell Thomas D Jr of 25000 shares of Regencell Bioscience at 14.76 subject to Rule 16b-3 | ||
Kaplan Stephen A over six months ago Acquisition by Kaplan Stephen A of 10000 shares of Regencell Bioscience at 14.87 subject to Rule 16b-3 | ||
Brandow Peter B over six months ago Disposition of 1564 shares by Brandow Peter B of Regencell Bioscience at 22.97 subject to Rule 16b-3 | ||
Amy Miles over six months ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over a year ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Regencell Bioscience Earnings per Share Projection vs Actual
Regencell Bioscience Corporate Management
Wai Chung | COO Officer | Profile | |
Tien Chau | Executive Officer | Profile | |
Michelle Chan | Financial Controller | Profile | |
YatPui Au | Chief Officer | Profile | |
YatGai Au | Chairman Founder | Profile | |
Antonia Assang | Senior Management | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.